Trials / Unknown
UnknownNCT05606380
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Advanced/Metastatic Solid Tumors or Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open, dose escalation phase I clinical study. Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX60 intravenous infusion, every 3 weeks, treatment until lose clinical benefit, toxicity, death, revocation of informed consent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX60 | HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks. |
Timeline
- Start date
- 2022-12-02
- Primary completion
- 2024-08-01
- Completion
- 2025-02-01
- First posted
- 2022-11-04
- Last updated
- 2024-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05606380. Inclusion in this directory is not an endorsement.